Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0VENOC |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | hu5B1 |
|||||
| Synonyms |
hu5B1
Click to Show/Hide
|
|||||
| Antigen Name | Undisclosed |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
hu5B1-TCO [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Adults (≥18) with histologically confirmed pancreatic/bladder/GI tumors or imaging-suspected PDAC
|
||||
| Administration Dosage |
On study day 0, a single slow infusion of hu5B1-TCO will be administered intravenously. Subsequently, either 3 days (n = 3) or 5 days (n = 3) later, a single slow infusion of 64Cu-Tz-SarAr will be administered intravenously.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05737615 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I Study of Pretargeted PET Imaging Using 64Cu-Tz-SarAr and a Trans-Cyclooctene-Modified Humanized 5B1 Immunoconjugate (hu5B1-TCO) in Patients With Pancreatic, Bladder Cancer, Gastrointestinal Malignancies or Solid Tumors With Elevated CA19-9
|
||||
| Primary Endpoint |
Primary endpoint is SUV mean measurement across multiple organs (heart, liver, spleen, kidney, lung, and other uptake sites) [Time Frame: 28 months].
|
||||
References